CL2012001145A1 - Método para liberar un polisacárido capsular a partir de células tipo 5 o tipo 8 de staphilococcus aureus, que comprende la etapa de tratar las células con un ácido; proceso para purificar dicho polisacárido; composición que comprende estos polisacáridos. - Google Patents

Método para liberar un polisacárido capsular a partir de células tipo 5 o tipo 8 de staphilococcus aureus, que comprende la etapa de tratar las células con un ácido; proceso para purificar dicho polisacárido; composición que comprende estos polisacáridos.

Info

Publication number
CL2012001145A1
CL2012001145A1 CL2012001145A CL2012001145A CL2012001145A1 CL 2012001145 A1 CL2012001145 A1 CL 2012001145A1 CL 2012001145 A CL2012001145 A CL 2012001145A CL 2012001145 A CL2012001145 A CL 2012001145A CL 2012001145 A1 CL2012001145 A1 CL 2012001145A1
Authority
CL
Chile
Prior art keywords
cells
type
polysaccharide
polysaccharides
purify
Prior art date
Application number
CL2012001145A
Other languages
English (en)
Spanish (es)
Inventor
Paolo Constantino
Maria Rosana Romano
Francesco Berti
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43513776&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012001145(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2012001145A1 publication Critical patent/CL2012001145A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • C07H1/08—Separation; Purification from natural products
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • External Artificial Organs (AREA)
CL2012001145A 2009-10-30 2012-04-30 Método para liberar un polisacárido capsular a partir de células tipo 5 o tipo 8 de staphilococcus aureus, que comprende la etapa de tratar las células con un ácido; proceso para purificar dicho polisacárido; composición que comprende estos polisacáridos. CL2012001145A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25690509P 2009-10-30 2009-10-30

Publications (1)

Publication Number Publication Date
CL2012001145A1 true CL2012001145A1 (es) 2012-09-14

Family

ID=43513776

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012001145A CL2012001145A1 (es) 2009-10-30 2012-04-30 Método para liberar un polisacárido capsular a partir de células tipo 5 o tipo 8 de staphilococcus aureus, que comprende la etapa de tratar las células con un ácido; proceso para purificar dicho polisacárido; composición que comprende estos polisacáridos.

Country Status (23)

Country Link
US (5) US9060965B2 (enExample)
EP (2) EP3199177A1 (enExample)
JP (4) JP5914344B2 (enExample)
CN (2) CN109134677A (enExample)
AU (1) AU2010310919B2 (enExample)
BR (2) BR122019005883A8 (enExample)
CA (1) CA2779578A1 (enExample)
CL (1) CL2012001145A1 (enExample)
CY (1) CY1118905T1 (enExample)
DK (1) DK2493498T3 (enExample)
ES (1) ES2626416T3 (enExample)
HR (1) HRP20170674T1 (enExample)
HU (1) HUE034251T2 (enExample)
LT (1) LT2493498T (enExample)
MX (2) MX345967B (enExample)
PL (1) PL2493498T3 (enExample)
PT (1) PT2493498T (enExample)
RS (1) RS56000B1 (enExample)
RU (1) RU2579900C2 (enExample)
SG (1) SG10201407096RA (enExample)
SI (1) SI2493498T1 (enExample)
SM (1) SMT201700275T1 (enExample)
WO (1) WO2011051917A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180221466A9 (en) * 2006-06-12 2018-08-09 Glaxosmithkline Biologicals S.A. Use of alpha-toxin for treating and preventing staphylococcus infections
EP3461496B1 (en) 2009-06-22 2023-08-23 Wyeth LLC Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
PE20110023A1 (es) 2009-06-22 2011-01-31 Wyeth Llc Composiciones inmunogenicas de antigenos de staphylococcus aureus
CA2779798C (en) * 2009-09-30 2019-03-19 Novartis Ag Conjugation of staphylococcus aureus type 5 and type 8 capsular polysaccharides
PL2493498T3 (pl) 2009-10-30 2017-08-31 Glaxosmithkline Biologicals Sa Oczyszczanie sacharydów otoczkowych staphylococcus aureus typu 5 i typu 8
AU2012214677B2 (en) * 2011-02-08 2016-11-10 Abvacc, Inc. Immunogenic composition comprising alpha-hemolysin oligopeptides
CN102660602B (zh) * 2012-04-17 2015-03-25 江苏康泰生物医学技术有限公司 快速纯化细菌荚膜多糖的方法
ES2737024T3 (es) * 2012-08-31 2020-01-09 Glaxosmithkline Biologicals Sa Proteínas estabilizadas para inmunización contra Staphylococcus aureus
GB201310008D0 (en) 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
WO2015010185A1 (en) * 2013-07-26 2015-01-29 University Of Saskatchewan Methods for producing salmonella o- antigen capsules, compositions and uses thereof
EP3229833A1 (en) 2014-12-10 2017-10-18 GlaxoSmithKline Biologicals SA Method of treatment
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
US12473379B2 (en) 2019-09-06 2025-11-18 Serum Institute Of India Private Limited Method for obtaining purified bacterial polysaccharides
US10828360B1 (en) * 2020-02-04 2020-11-10 OneBioPharma, Inc. Methods for inhibiting biofilm formation
KR20220144393A (ko) 2020-02-21 2022-10-26 화이자 인코포레이티드 당류의 정제
US20230383324A1 (en) 2020-10-22 2023-11-30 Pfizer Inc. Methods for purifying bacterial polysaccharides
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
CN112986457B (zh) * 2021-02-25 2022-07-12 中国食品药品检定研究院 HPSEC-MALS法检测多糖并与Sepharose CL-4B法关联的方法
CN118345133A (zh) * 2021-06-15 2024-07-16 广州知易生物科技有限公司 脆弱拟杆菌荚膜多糖a的制备方法
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
CN114957509B (zh) * 2022-08-01 2022-10-21 深圳柏垠生物科技有限公司 一种可放大的可拉酸纯化方法

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2166963A (en) * 1936-11-19 1939-07-25 Sharp & Dohme Inc Antigenic polysaccharide complex
CH417852A (fr) * 1961-05-15 1966-07-31 Parke Davis & Co Procédé de préparation d'un antigène staphylococcique
US3269913A (en) * 1962-05-11 1966-08-30 Parke Davis & Co Staphylococcal-immunizing products and methods for their production
GB995338A (en) 1963-09-20 1965-06-16 Parke Davis & Co Polysaccharides and methods for their production
JPS5452794A (en) 1977-09-30 1979-04-25 Kousaku Yoshida Extracting of polysacchride from capusle containing epidermis staphylococus
US4663160A (en) * 1983-03-14 1987-05-05 Miles Laboratories, Inc. Vaccines for gram-negative bacteria
US4808700A (en) * 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
US5055455A (en) * 1988-09-28 1991-10-08 Brigham And Women's Hospital Capsular polysaccharide adhesin antigen, preparation, purification and use
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
CA2006700A1 (en) 1989-01-17 1990-07-17 Antonello Pessi Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
EP0482068A1 (en) 1989-07-14 1992-04-29 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
DE69113564T2 (de) 1990-08-13 1996-05-30 American Cyanamid Co Faser-Hemagglutinin von Bordetella pertussis als Träger für konjugierten Impfstoff.
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
FR2682388B1 (fr) 1991-10-10 1995-06-09 Pasteur Merieux Serums Vacc Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal.
AU681573B2 (en) * 1991-11-22 1997-09-04 Glaxosmithkline Biologicals Sa Type I and type II surface antigens associated with (staphylococcus epidermidis)
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
US5679654A (en) * 1994-09-02 1997-10-21 Brigham & Women's Hospital, Inc. Capsular polysaccharide immunomodulator
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
US6743430B1 (en) * 1995-03-29 2004-06-01 Richard E. Parizek Multicomponent vaccine containing clostridial and non-clostridial organisms in a low dose
PT1090642E (pt) 1995-06-07 2008-09-09 Glaxosmithkline Biolog Sa Vacinas compreendendo um conjugado de antigénio polissacarídico - proteína veículo e proteína veículo livre
US5770208A (en) 1996-09-11 1998-06-23 Nabi Staphylococcus aureus B-linked hexosamine antigen
US6294177B1 (en) * 1996-09-11 2001-09-25 Nabi Staphylococcus aureus antigen-containing whole cell vaccine
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
JP2001519817A (ja) 1997-03-26 2001-10-23 ブリガム アンド ウイメンズ ホスピタル 糖断片生成法
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
ATE476508T1 (de) 1997-11-06 2010-08-15 Novartis Vaccines & Diagnostic Neisseriale antigene
KR20010032336A (ko) 1997-11-21 2001-04-16 브랑디 빠스깔 클라미디아 뉴모니아 게놈 서열과 폴리펩티드, 이의 단편및 이의 용도, 특히, 감염의 진단, 예방 및 치료 용도
JP2002517179A (ja) 1997-11-28 2002-06-18 ジェンセット Ｃｈｌａｍｙｄｉａｔｒａｃｈｏｍａｔｉｓゲノム配列およびポリペプチド、それらのフラグメント、ならびに特に感染症の診断、予防および治療のためのそれらの使用
JP4399112B2 (ja) 1998-01-14 2010-01-13 カイロン ソチエタ ア レスポンサビリタ リミタータ ＮｅｉｓｓｅｒｉａＭｅｎｉｎｇｉｔｉｄｉｓ抗原
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
GB9808932D0 (en) * 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
EP2261357A3 (en) 1998-05-01 2012-01-11 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
US7252828B2 (en) * 1998-07-15 2007-08-07 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
JP2004511201A (ja) 1998-10-09 2004-04-15 カイロン　コーポレイション ナイセリアゲノム配列およびそれらの使用方法
JP2002529069A (ja) 1998-11-12 2002-09-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア クラミジア・ニューモニエのゲノム配列
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
US6146902A (en) 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
TWI281403B (en) 1999-03-19 2007-05-21 Smithkline Beecham Biolog Vaccine
US6936258B1 (en) 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
AU781027B2 (en) 1999-04-09 2005-04-28 Department Of Health & Human Services Recombinant toxin a protein carrier for polysaccharide conjugate vaccines
US7534866B2 (en) 2005-10-19 2009-05-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
US6689567B1 (en) * 1999-05-28 2004-02-10 University Of Guelph Method for assaying the function of FlaA1 and WbpM
US8273360B2 (en) 2000-01-17 2012-09-25 Novartis Ag Outer membrane vesicle (OMV) vaccine comprising N. meningitidis serogroup B outer membrane proteins
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
CA2414884A1 (en) 2000-07-03 2002-01-10 Chiron S.P.A. Immunisation against chlamydia pneumoniae
EP2277894A1 (en) 2000-10-27 2011-01-26 Novartis Vaccines and Diagnostics S.r.l. Nucleic acids and proteins from streptococcus groups A & B
WO2002091998A2 (en) 2001-05-11 2002-11-21 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
US6537577B1 (en) * 2001-06-04 2003-03-25 Bio Medical Development Corporation Method of prophylaxis for bovine mastitis
GB2379996B (en) * 2001-06-05 2004-05-19 Tayside Flow Technologies Ltd Flow means
EP1395648B1 (en) * 2001-06-11 2009-04-22 Applied NanoSystems B.V. Methods for binding acma-type protein anchor fusions to cell-wall material of micro-organisms
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
US20040161741A1 (en) 2001-06-30 2004-08-19 Elazar Rabani Novel compositions and processes for analyte detection, quantification and amplification
US20030113350A1 (en) 2001-09-19 2003-06-19 Fattom Ali I. Glycoconjugate vaccines for use in immune-compromised populations
GB0210128D0 (en) 2002-05-02 2002-06-12 Chiron Spa Nucleic acids and proteins from streptococcus groups A & B
WO2004011027A1 (en) 2002-07-30 2004-02-05 Baxter International Inc. Chimeric multivalent polysaccharide conjugate vaccines
US20060121058A1 (en) * 2002-08-08 2006-06-08 Children's Medical Center Corporation Anti-pneumococcal preparations
AU2003260102A1 (en) 2002-08-26 2004-03-11 Chiron Corporation Conserved and specific streptococcal genomes
GB0220198D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture
ES2504166T3 (es) 2002-09-13 2014-10-08 Novartis Vaccines And Diagnostics, Inc. Vacuna de estreptococo del grupo B
CA2501077C (en) * 2002-11-12 2016-06-21 Gerald B. Pier Polysaccharide vaccine for staphylococcal infections
AU2003290867A1 (en) 2002-11-12 2004-06-03 The Brigham And Women's Hospital, Inc. Methods and products for treating staphylococcal infections
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
NZ561879A (en) 2003-03-07 2009-05-31 Wyeth Corp Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
JP4597123B2 (ja) 2003-03-13 2010-12-15 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 細菌性細胞溶解素の精製方法
WO2005000346A1 (en) 2003-06-23 2005-01-06 Baxter International Inc. Carrier proteins for vaccines
NZ544542A (en) 2003-07-24 2009-01-31 Merck & Co Inc Polypeptides for inducing a protective immune response against staphylococcus aureus
US20060188515A1 (en) 2003-07-24 2006-08-24 Anderson Annaliesa S Polypeptides for inducing a protective immune response against staphylococcus aureus
US8048432B2 (en) * 2003-08-06 2011-11-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
EP1664319B1 (en) * 2003-09-11 2010-03-10 De Staat der Nederlanden, vert. door de minister van VWS Process for producing a capsular polysaccharide for use in conjugate vaccines
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
CA2555342A1 (en) 2004-02-18 2005-09-01 Merck & Co., Inc. Polypeptides for inducing a protective immune response against staphylococcus aureus
WO2005086663A2 (en) 2004-02-27 2005-09-22 Merck & Co., Inc. Polypeptides for inducing a protective immune response against staphlococcus aureus
US20050250821A1 (en) * 2004-04-16 2005-11-10 Vincent Sewalt Quaternary ammonium compounds in the treatment of water and as antimicrobial wash
US7842479B2 (en) * 2004-05-21 2010-11-30 The Board Of Regents Of The University Of Nebraska Methods for altering acetic acid production and enhancing cell death in bacteria
EP1753441A2 (en) 2004-05-25 2007-02-21 Merck & Co., Inc. Polypeptides for inducing a protective immune response against staphylococcus aureus
GB0413868D0 (en) * 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
WO2006033918A2 (en) 2004-09-17 2006-03-30 Merck & Co., Inc. Polypeptides for inducing a protective immune response against staphylococcus aureus
EP2893938B1 (en) 2004-09-22 2019-03-06 GlaxoSmithKline Biologicals SA Immunogenic composition for use in vaccination against Staphylococcei
US20060134141A1 (en) 2004-12-14 2006-06-22 Nabi Biopharmaceuticals Glycoconjugate vaccines containing peptidoglycan
EP1843785B1 (en) 2005-01-21 2016-07-27 Merck Sharp & Dohme Corp. Polypeptides for inducing a protective immune response against staphylococcus aureus
GB0502096D0 (en) * 2005-02-01 2005-03-09 Chiron Srl Purification of streptococcal capsular polysaccharide
US20060228368A1 (en) 2005-04-07 2006-10-12 Nabi Biopharmaceuticals Method of protecting against staphylococcal infection
FR2884830A1 (fr) 2005-04-25 2006-10-27 Sanofi Pasteur Sa Procede de production de souches de staphylococcus aureus surproductrices
ATE536884T1 (de) * 2005-06-27 2011-12-15 Glaxosmithkline Biolog Sa Immunogene zusammensetzung
WO2007023386A2 (en) * 2005-08-24 2007-03-01 Novartis Vaccines And Diagnostics Srl Zwitterionization of capsular saccharides
GB0526038D0 (en) 2005-12-21 2006-02-01 Glaxosmithkline Biolog Sa Immunogenic composition
JP5286089B2 (ja) * 2006-01-13 2013-09-11 バクスター・インターナショナル・インコーポレイテッド ポリサッカライドを精製する方法
AR060188A1 (es) 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa Procedimiento de conjugacion
EP2476433A1 (en) * 2006-03-30 2012-07-18 GlaxoSmithKline Biologicals S.A. Immunogenic composition
FR2899110A1 (fr) 2006-03-31 2007-10-05 Sanofi Pasteur Sa Polysaccharides capsulaires de type 5 et de type 8 des souches surproductrices de staphylococcus aureus
EP2043690A1 (en) 2006-06-12 2009-04-08 Nabi Biopharmaceuticals Use of alpha-toxin for treating and preventing staphylococcus infections
GB0612854D0 (en) * 2006-06-28 2006-08-09 Novartis Ag Saccharide analysis
WO2008152447A2 (en) 2006-10-30 2008-12-18 The University Of Western Ontario Staphylococcus aureus specific anti-infectives
EP2094317B1 (en) * 2006-11-08 2010-09-15 B-K Medical ApS Method for multi-step sterilization
DE102006062398A1 (de) 2006-12-20 2008-06-26 Edi (Experimentelle & Diagnostische Immunologie) Gmbh Verfahren zur Erkennung und/oder Charakterisierung zellulärer Aktivitätsmuster, Verwendung von Toll-like-Rezeptor-Liganden (TLR-Liganden) und ein Kit
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
GB0700135D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Vaccine
CN101679516B (zh) 2007-05-31 2013-11-13 默沙东公司 靶向金黄色葡萄球菌ORF0657n的抗原结合蛋白
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
EP2666784B1 (en) 2007-08-31 2017-04-05 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
EP2254592B1 (en) 2008-02-28 2019-06-05 Dako Denmark A/S Mhc multimers in borrelia diagnostics and disease
NZ591633A (en) * 2008-09-17 2012-10-26 Novartis Ag Combination gas vaccines and therapeutics
WO2010042481A1 (en) * 2008-10-06 2010-04-15 University Of Chicago Compositions and methods related to bacterial eap, emp, and/or adsa proteins
WO2010132833A1 (en) * 2009-05-14 2010-11-18 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
EP3461496B1 (en) * 2009-06-22 2023-08-23 Wyeth LLC Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
PE20110023A1 (es) 2009-06-22 2011-01-31 Wyeth Llc Composiciones inmunogenicas de antigenos de staphylococcus aureus
GB0913681D0 (en) * 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
CA2779798C (en) * 2009-09-30 2019-03-19 Novartis Ag Conjugation of staphylococcus aureus type 5 and type 8 capsular polysaccharides
PL2493498T3 (pl) * 2009-10-30 2017-08-31 Glaxosmithkline Biologicals Sa Oczyszczanie sacharydów otoczkowych staphylococcus aureus typu 5 i typu 8
US8679812B2 (en) * 2009-12-28 2014-03-25 Kikkoman Corporation Method for extracting Staphylococcus aureus antigen, reagent for extracting Staphylococcus aureus antigen, and method for assessing Staphylococcus aureus
EP2519265B1 (en) * 2009-12-30 2018-11-14 GlaxoSmithKline Biologicals SA Polysaccharide immunogens conjugated to e. coli carrier proteins
ES2655701T3 (es) * 2010-07-02 2018-02-21 The University Of Chicago Composiciones y métodos relacionados con variantes de la proteína A (SpA)
GB201310008D0 (en) * 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
JP2016540764A (ja) 2013-12-04 2016-12-28 グリコヴァキシン アーゲー 大腸菌で合成された糖タンパク質ワクチンによる黄色ブドウ球菌感染の予防
US9775872B2 (en) 2014-08-20 2017-10-03 Professional Compounding Centers Of America Topical pharmaceutical bases for preventing viral diseases
WO2018217564A1 (en) * 2017-05-22 2018-11-29 The Children's Medical Center Corporation Combined vaccine against mycobacterium tuberculosis

Also Published As

Publication number Publication date
US20120282295A1 (en) 2012-11-08
RU2579900C2 (ru) 2016-04-10
BR122019005883A8 (pt) 2022-10-04
JP2019104940A (ja) 2019-06-27
US20150315225A1 (en) 2015-11-05
CN109134677A (zh) 2019-01-04
LT2493498T (lt) 2017-05-25
US11208424B2 (en) 2021-12-28
PL2493498T3 (pl) 2017-08-31
EP2493498A1 (en) 2012-09-05
BR112012010223A2 (pt) 2016-12-06
JP2016047852A (ja) 2016-04-07
RU2012122237A (ru) 2013-12-10
HUE034251T2 (en) 2018-02-28
MX2012004851A (es) 2012-05-22
JP5914344B2 (ja) 2016-05-11
CN102971009A (zh) 2013-03-13
US9441004B2 (en) 2016-09-13
CY1118905T1 (el) 2018-01-10
EP2493498B1 (en) 2017-03-22
WO2011051917A1 (en) 2011-05-05
BR122019005883A2 (enExample) 2019-09-03
MX345967B (es) 2017-02-28
PT2493498T (pt) 2017-05-24
ES2626416T3 (es) 2017-07-25
HRP20170674T1 (hr) 2017-07-14
DK2493498T3 (en) 2017-05-08
SI2493498T1 (sl) 2017-07-31
AU2010310919B2 (en) 2015-05-07
JP2013509397A (ja) 2013-03-14
US20220089627A1 (en) 2022-03-24
SMT201700275T1 (it) 2017-07-18
US20160376301A1 (en) 2016-12-29
US20190169216A1 (en) 2019-06-06
EP3199177A1 (en) 2017-08-02
JP2017206564A (ja) 2017-11-24
CA2779578A1 (en) 2011-05-05
AU2010310919A1 (en) 2012-05-24
SG10201407096RA (en) 2014-12-30
US9060965B2 (en) 2015-06-23
RS56000B1 (sr) 2017-09-29

Similar Documents

Publication Publication Date Title
CL2012001145A1 (es) Método para liberar un polisacárido capsular a partir de células tipo 5 o tipo 8 de staphilococcus aureus, que comprende la etapa de tratar las células con un ácido; proceso para purificar dicho polisacárido; composición que comprende estos polisacáridos.
UY39011A (es) Métodos para purificar cannabinoides, composiciones y kits de estos
BR112012010371A2 (pt) estruturas fibrosas com baixa formação de fiapos, e métodos para fabricação dos mesmos
EA201201648A1 (ru) Стимуляторы sgc
ECSP13012420A (es) Derivados de tetrahidro-pirido-pirimidina
CR20120341A (es) Mezclas de plaguicidas
CL2012002627A1 (es) Metodos para aumentar la tolerancia al estres abiotico y/o reducir las consecuencias del estres abiotico en plantas que comprende ponerla en contacto con una composicion que contiene acido dicarboxilico o un derivado.
BR112014015910A2 (pt) composição
MX2014001717A (es) Composiciones inmunoterapeuticas de levadura-mucina 1 (muc1) y usos de las mismas.
BRPI0810431A8 (pt) Processo para utilização aperfeiçoada do potencial de produção de plantas transgênicas
MX2016017355A (es) Lipido que comprende acido docosapentaenoico.
BRPI0909040A8 (pt) Derivados de azetidina e ciclobutano, seus usos, e composição
CY1124624T1 (el) Μητρες οι οποιες περιεχουν εναν τροποποιημενο πολυσακχαριτη
BR112018007070A2 (pt) método, composição e kit para a preparação de uma planta a partir de um protoplasto, planta regenerada e composição para clivagem de dna
BR112013031307A2 (pt) métodos para tratamento de material lignocelulósico
BR112017005997A2 (pt) método
NI201400022A (es) Composición farmacéutica que comprende un ciclopolisacárido
BR112014031051A2 (pt) processo para produção de uma composição contendo folistatina ativa
BR112016016539A2 (pt) micro-organismos recombinantes enriquecidos com carboidratos
PA8676401A1 (es) Metodos para purificar tigeciclina
BR112017011422A2 (pt) compostos de ácido isoazol hidro¬xâmico como inibidores de lpxc
CL2016000905A1 (es) Disminución del contenido de ácidos grasos saturados de semillas de plantas (solicitud divisional de 3665-2012).
BR112013012795B8 (pt) processo de tratamento de produtos vegetais e composição
CL2013001621A1 (es) Molecula de acido nucleico reguladora con especificidad definida, construccion de expresion que la comprende, vector; microorganismo, celula vegetal o animal; y metodo para la produccion de dicha molecula.
MX2015016057A (es) Solucion estabilizada de acido hipocloroso y uso de la misma.